Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Investigation of the pharmacokinetic interaction between ritonavir and CMDCK, a new non-nucleoside reverse transcriptase inhibitor.

Zhuang XM, Shen GL, Yuan M, Li H.

Drug Res (Stuttg). 2013 May;63(5):237-42. doi: 10.1055/s-0033-1334924. Epub 2013 Mar 28.

PMID:
23539429
2.

[Metabolism of 3-cyanomethyl-4-methyl-DCK, a new anti-HIV candidate, in human intestinal microsomes].

Zhuang XM, Wen YY, Li H, Deng JT, Kong WL, Tian XT, Cui SL, Xie L.

Yao Xue Xue Bao. 2010 Sep;45(9):1116-22. Chinese.

PMID:
21351567
3.

Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P.

J Clin Pharm Ther. 2012 Feb;37(1):81-8. doi: 10.1111/j.1365-2710.2010.01235.x. Epub 2010 Dec 5.

PMID:
21128991
4.
5.

Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.

Zhuang XM, Deng JT, Li H, Kong WL, Ruan JX, Xie L.

Acta Pharmacol Sin. 2011 Oct;32(10):1276-84. doi: 10.1038/aps.2011.91.

6.

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, Johnson M, Zhou XJ, Pietropaolo K, Mayers D.

Br J Clin Pharmacol. 2012 Aug;74(2):336-45. doi: 10.1111/j.1365-2125.2012.04194.x.

7.

Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.

Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA.

J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71.

8.

Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.

Solon EG, Balani SK, Luo G, Yang TJ, Haines PJ, Wang L, Demond T, Diamond S, Christ DD, Gan LS, Lee FW.

Drug Metab Dispos. 2002 Nov;30(11):1164-9.

9.

Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.

Ravi PR, Vats R, Thakur R, Srivani S, Aditya N.

Phytother Res. 2012 Oct;26(10):1490-5. doi: 10.1002/ptr.4593. Epub 2012 Feb 4.

PMID:
22308076
10.

HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.

Berginc K, Trdan T, Trontelj J, Kristl A.

Biopharm Drug Dispos. 2010 Nov;31(8-9):495-505. doi: 10.1002/bdd.730. Epub 2010 Oct 26.

PMID:
21104925
11.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
12.

Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.

Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, Zhou SF.

Curr Drug Metab. 2007 May;8(4):325-40.

PMID:
17504222
13.

Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds.

Lewi P, Arnold E, Andries K, Bohets H, Borghys H, Clark A, Daeyaert F, Das K, de Béthune MP, de Jonge M, Heeres J, Koymans L, Leempoels J, Peeters J, Timmerman P, Van den Broeck W, Vanhoutte F, Van't Klooster G, Vinkers M, Volovik Y, Janssen PA.

Drugs R D. 2004;5(5):245-57.

PMID:
15357624
14.

A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.

Lledó-García R, Nácher A, Casabó VG, Merino-Sanjuán M.

Drug Metab Dispos. 2011 Feb;39(2):294-301. doi: 10.1124/dmd.110.034488. Epub 2010 Oct 26.

15.

In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

Patel J, Buddha B, Dey S, Pal D, Mitra AK.

Am J Ther. 2004 Jul-Aug;11(4):262-77.

PMID:
15266218
16.

pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.

Kis O, Zastre JA, Ramaswamy M, Bendayan R.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22. doi: 10.1124/jpet.110.166314. Epub 2010 May 27.

17.

Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.

Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):221-7. doi: 10.1016/j.bbrc.2013.08.054. Epub 2013 Aug 24.

PMID:
23981805
18.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH.

Br J Pharmacol. 2010 Jul;160(5):1224-33. doi: 10.1111/j.1476-5381.2010.00759.x.

19.

Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats.

Hirunpanich V, Katagi J, Sethabouppha B, Sato H.

Drug Metab Dispos. 2006 Feb;34(2):305-10. Epub 2005 Nov 18.

20.

Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.

Colucci P, Pottage JC, Robison H, Turgeon J, Ducharme MP.

Antimicrob Agents Chemother. 2009 Feb;53(2):646-50. doi: 10.1128/AAC.00905-08. Epub 2008 Nov 17.

Items per page

Supplemental Content

Write to the Help Desk